IDO and TDO inhibitors appear to be potentially viable therapeutically approaches to prevent the development of delirium, to slow cognitive impairment, and reduce depression and the accumulation of amyloid-forming proteins. The gene discussed is IDO1; the disease is Cognitive impairment.